{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:14:59Z","timestamp":1787627699191,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.purol.2021.04.009","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T04:14:56Z","timestamp":1623989696000},"page":"1072-1079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacit\u00e9 et tol\u00e9rance des traitements locaux en injections pour le traitement de la maladie de La Peyronie\u00a0: revue de la litt\u00e9rature"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5405-0017","authenticated-orcid":false,"given":"X.","family":"Rod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Akakpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.purol.2021.04.009_bib0195","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU guidelines on penile curvature","volume":"62","author":"Hatzimouratidis","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2021.04.009_bib0200","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","article-title":"Peyronie's Disease: AUA Guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.purol.2021.04.009_bib0205","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2021.04.009_bib0210","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41443-018-0029-3","article-title":"The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronie's Disease (PD)","volume":"30","author":"Burri","year":"2018","journal-title":"Int J Impot Res"},{"issue":"3","key":"10.1016\/j.purol.2021.04.009_bib0215","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1743-6109.2012.02999.x","article-title":"Psychological impact of Peyronie's disease: a review","volume":"10","author":"Nelson","year":"2013","journal-title":"J Sex Med"},{"issue":"3","key":"10.1016\/j.purol.2021.04.009_bib0220","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/tau.2016.05.14","article-title":"Psychological aspects of Peyronie's disease","volume":"5","author":"Terrier","year":"2016","journal-title":"Transl Androl Urol"},{"issue":"8","key":"10.1016\/j.purol.2021.04.009_bib0225","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/j.1743-6109.2008.00883.x","article-title":"Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls","volume":"5","author":"Rosen","year":"2008","journal-title":"J Sex Med"},{"issue":"6","key":"10.1016\/j.purol.2021.04.009_bib0230","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0022-5347(17)39746-X","article-title":"The natural history of Peyronie's disease","volume":"144","author":"Gelbard","year":"1990","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2021.04.009_bib0235","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.sxmr.2019.02.004","article-title":"Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease","volume":"7","author":"Milenkovic","year":"2019","journal-title":"Sex Med Rev"},{"issue":"1","key":"10.1016\/j.purol.2021.04.009_bib0240","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/187152812798889321","article-title":"Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic \u201crationale\u201d and related emerging treatment strategies","volume":"11","author":"Paulis","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"5","key":"10.1016\/j.purol.2021.04.009_bib0245","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1080\/13685538.2019.1643311","article-title":"Glimpses into the molecular pathogenesis of Peyronie's disease","volume":"23","author":"Ten Dam","year":"2020","journal-title":"Aging Male"},{"issue":"2","key":"10.1016\/j.purol.2021.04.009_bib0250","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00345-019-02815-6","article-title":"A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie's disease","volume":"38","author":"Patel","year":"2020","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.purol.2021.04.009_bib0255","doi-asserted-by":"crossref","first-page":"E197","DOI":"10.5489\/cuaj.5255","article-title":"2018\u00a0Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature","volume":"12","author":"Bella","year":"2018","journal-title":"Can Urol Assoc J J Assoc Urol Can"},{"key":"10.1016\/j.purol.2021.04.009_bib0260","doi-asserted-by":"crossref","unstructured":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D.PLoS Med. 2009;6(7):e1000100. doi: 10.1371\/journal.pmed.1000100. Epub 2009 Jul 21.PMID: 19621070","DOI":"10.1371\/journal.pmed.1000100"},{"issue":"5","key":"10.1016\/j.purol.2021.04.009_bib0265","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0022-4804(90)90197-A","article-title":"Calcium antagonists retard extracellular matrix production in connective tissue equivalent","volume":"49","author":"Lee","year":"1990","journal-title":"J Surg Res"},{"issue":"3","key":"10.1016\/j.purol.2021.04.009_bib0270","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi","year":"2009","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"10.1016\/j.purol.2021.04.009_bib0275","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study","volume":"51","author":"Rehman","year":"1998","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.purol.2021.04.009_bib0280","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1111\/j.1743-6109.2010.01924.x","article-title":"Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial","volume":"7","author":"Soh","year":"2010","journal-title":"J Sex Med"},{"issue":"2","key":"10.1016\/j.purol.2021.04.009_bib0285","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/00365599109024539","article-title":"Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma","volume":"25","author":"Duncan","year":"1991","journal-title":"Scand J Urol Nephrol"},{"issue":"1","key":"10.1016\/j.purol.2021.04.009_bib0290","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.purol.2021.04.009_bib0295","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/j.1939-4640.1996.tb01757.x","article-title":"Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie's disease and veno-occlusive dysfunction","volume":"17","author":"Gentile","year":"1996","journal-title":"J Androl"},{"issue":"4","key":"10.1016\/j.purol.2021.04.009_bib0300","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/smrj.54","article-title":"The History of Collagenase Clostridium Histolyticum","volume":"3","author":"Yang","year":"2015","journal-title":"Sex Med Rev"},{"issue":"3","key":"10.1016\/j.purol.2021.04.009_bib0305","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0363-5023(96)80368-6","article-title":"Collagenase in the treatment of Dupuytren's disease: an in vitro study","volume":"21","author":"Starkweather","year":"1996","journal-title":"J Hand Surg"},{"issue":"4","key":"10.1016\/j.purol.2021.04.009_bib0310","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/jhsu.2000.6918","article-title":"Enzyme injection as nonsurgical treatment of Dupuytren's disease","volume":"25","author":"Badalamente","year":"2000","journal-title":"J Hand Surg"},{"issue":"1","key":"10.1016\/j.purol.2021.04.009_bib0315","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","article-title":"Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study","volume":"149","author":"Gelbard","year":"1993","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.purol.2021.04.009_bib0320","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2\u00a0large double-blind, randomized, placebo controlled phase 3\u00a0studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2021.04.009_bib0325","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bju.13120","article-title":"Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD)","volume":"116","author":"Carson","year":"2015","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.purol.2021.04.009_bib0330","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bju.13932","article-title":"Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol","volume":"120","author":"Abdel Raheem","year":"2017","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.purol.2021.04.009_bib0335","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.sxmr.2019.05.001","article-title":"Discontinuation from Collagenase Clostridium histolyticum Therapy for Peyronie's Disease: Review and Single-Center Cohort Analysis","volume":"7","author":"Amighi","year":"2019","journal-title":"Sex Med Rev"},{"issue":"1","key":"10.1016\/j.purol.2021.04.009_bib0340","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/jsm.12721","article-title":"Surgical correction of persistent Peyronie's disease following collagenase clostridium histolyticum treatment","volume":"12","author":"Levine","year":"2015","journal-title":"J Sex Med"},{"key":"10.1016\/j.purol.2021.04.009_bib0345","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.urology.2017.08.037","article-title":"Successful Treatment of Residual Curvature in Peyronie Disease in Men Previously Treated With Intralesional Collagenase Clostridium Histolyticum","volume":"110","author":"DeLay","year":"2017","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.purol.2021.04.009_bib0350","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11934-019-0910-8","article-title":"Outcomes of Surgery in Peyronie's Disease Following Intralesional Collagenase Clostridium Histolyticum Injections","volume":"20","author":"Bazzi","year":"2019","journal-title":"Curr Urol Rep"},{"issue":"4","key":"10.1016\/j.purol.2021.04.009_bib0365","first-page":"165","article-title":"[Betamethasone versus placebo in Peyronie's disease]","volume":"70","author":"Cipollone","year":"1998","journal-title":"Arch Ital Urol Androl Organo Uff Soc Ital Ecogr Urol E Nefrol"},{"issue":"3","key":"10.1016\/j.purol.2021.04.009_bib0370","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JU.0000000000000245","article-title":"Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial","volume":"202","author":"Ziegelmann","year":"2019","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2021.04.009_bib0375","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bju.14602","article-title":"Penile traction therapy with the new device \u201cPenimaster PRO\u201d is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study","volume":"123","author":"Moncada","year":"2019","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.purol.2021.04.009_bib0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5582\/irdr.2019.01130","article-title":"Advances in stem cell therapy for the treatment of Peyronie's disease","volume":"9","author":"Moussa","year":"2020","journal-title":"Intractable Rare Dis Res"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708721001172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708721001172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:34:45Z","timestamp":1761114885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708721001172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":36,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1166708721001172"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2021.04.009","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacit\u00e9 et tol\u00e9rance des traitements locaux en injections pour le traitement de la maladie de La Peyronie\u00a0: revue de la litt\u00e9rature","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2021.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}